Hospital Regional Universitario de Malaga

Málaga 29016

20 studies enrolling now · 96 studies all time

What they study most

ALK+ Advanced NSCLC, Acute Myeloid Leukemia, Adenovirus Infection, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer, Advanced Solid Tumor, Advanced Squamous Non-Small Cell Lung Carcinoma, Amyotrophic Lateral Sclerosis (ALS), Anaplastic Lymphoma Kinase-positive, Arthritis, Rheumatoid, Atopic Dermatitis, BK Virus Infection

Studies at this site

• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer — Recruiting now
• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer — Recruiting now
• Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects — Recruiting now
• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines — Recruiting now
• A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) — Recruiting now
• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer — Recruiting now
• PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS — Recruiting now
• Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer — Recruiting now
• Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC — Recruiting now
• First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors — Recruiting now
• An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED — Recruiting now
• Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer — Recruiting now
• Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis — Recruiting now
• Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer — Recruiting now
• LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC — Recruiting now
• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation — Recruiting now
• The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials — Recruiting now
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) — Recruiting now
• Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) — Recruiting now
• A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) — Recruiting now
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Running, not enrolling
• A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors — Running, not enrolling
• Phase III Study of AK112 for NSCLC Patients — Running, not enrolling
• Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis — Completed
• Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) — Running, not enrolling
• Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) — Running, not enrolling
• A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors — Running, not enrolling
• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) — Running, not enrolling
• Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures — Completed
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML — Running, not enrolling
• A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer — Running, not enrolling
• A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis — Running, not enrolling
• A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease — Running, not enrolling
• A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation — Running, not enrolling
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer — Stopped early
• A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) — Stopped early
• A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) — Running, not enrolling
• Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma — Running, not enrolling
• A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment — Completed
• A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) — Completed
• A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A — Running, not enrolling
• A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer — Completed
• Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — Running, not enrolling
• Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC — Running, not enrolling
• Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy — Completed
• A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a) — Running, not enrolling
• Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma — Stopped early
• A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) — Running, not enrolling